Isabelle Poizot‐Martin

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO* study

T Saint-Marc, M Partisani, Isabelle Poizot‐Martin et al. · AIDS · 2000 · 360 citations

Medicine, Clinical Sciences, Endocrinology +17

Incidence of Non–AIDS-Defining Cancers Before and During the Highly Active Antiretroviral Therapy Era in a Cohort of Human Immunodeficiency Virus–Infected Patients

Magid Herida, Murielle Mary‐Krause, R. Kaphan et al. · Journal of Clinical Oncology · 2003 · 338 citations

Public Health, Infectious Diseases, Oncology +11

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

Joseph J. Eron, Bonaventura Clotet, J. Durant et al. · The Journal of Infectious Diseases · 2012 · 312 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Visceral leishmaniasis and HIV-1 co-infection in southern France

Éric Rosenthal, Pierre Marty, Isabelle Poizot‐Martin et al. · Transactions of the Royal Society of Tropical Medicine and Hygiene · 1995 · 162 citations

Veterinary Medicine, Infectious Diseases, Pathology +16